* This is the Professional Version. *
Progressive Supranuclear Palsy
Progressive supranuclear palsy is a rare, degenerative CNS disorder that progressively impairs voluntary eye movements and causes bradykinesia, muscular rigidity with progressive axial dystonia, pseudobulbar palsy, and dementia.
The cause of progressive supranuclear palsy is unknown. Neurons in the basal ganglia and brain stem degenerate; neurofibrillary tangles containing an abnormally phosphorylated tau protein are also present. Multiple lacunar strokes in the basal ganglia and deep white matter can resemble progressive supranuclear palsy; however, this disorder is nondegenerative and progresses more gradually.
Symptoms usually begin in late middle age. The first symptom may be difficulty looking up or down without moving the neck or difficulty climbing up and down stairs. Voluntary eye movements, particularly vertical, are difficult, but reflexive eye movements are unaffected. Movements are slowed, muscles become rigid, and axial dystonia develops. Patients tend to fall backward. Dysphagia and dysarthria with emotional lability (pseudobulbar palsy) are common. Resting tremor may develop. Dementia eventually occurs.
Many patients become incapacitated within about 5 yr and die within about 10 yr.
Treatment focuses on relieving symptoms but is unsatisfactory. Occasionally, levodopa and/or amantadine partially relieve rigidity. Physical and occupational therapy may help improve mobility and function and reduce the risk of falls.
Because the disorder is fatal, patients should be encouraged to prepare advance directives soon after the disorder is diagnosed. These directives should indicate what kind of medical care people want at the end of life (see Advance Directives).
Drug NameSelect Trade
amantadineNo US brand name
* This is a professional Version *